ArticleERJ open research2026
Lipid profiling in nontuberculous mycobacterial pulmonary disease based on geospatial locations and disease severity.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of lipid profiles in the pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM-PD) remains largely unexplored. This study aimed to identify lipid profile variations across geospatial lung lesions, their reflection in serum relative to disease severity and their diagnostic discriminative ability using lipidomic analysis. Methods: Lipidomics was performed using hydrophilic interaction liquid chromatography-tandem mass spectrometry on lung tissues and serum samples. 960 lipid species were analysed across geospatial lung lesions (cavity wall, centre of cavity, granuloma, bronchiectasis and normal lungs) and assessed in serum according to disease severity. Python-based machine-learning models in PyCaret were used to classify NTM-PD based on lipidomic signatures. Results: This study included 23 lung specimens from seven patients with NTM-PD and 332 serum samples comprising 134 patients with NTM-PD, 136 with non-NTM bronchiectasis and 62 healthy controls. Triacylglycerol (TG) levels were elevated in lung lesions affected by NTM-PD, particularly in the centre of the cavity. In serum, TG levels were higher in patients with NTM-PD than controls but decreased in patients with more severe disease, including those with acid-fast bacilli smear positivity, cavitation or higher BACES (body mass index, age, cavity, erythrocyte sedimentation rate and sex) scores. The top five models, developed using lipid species characteristically altered in NTM-PD, effectively discriminated patients with NTM-PD from healthy controls. Conclusion: TG levels were elevated in lung lesions affected by NTM-PD but decreased in serum as disease severity increased, suggesting TG accumulation in lung tissues. These findings highlighted the role of lipid metabolism in the pathogenesis of NTM-PD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.